United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

zentiva - tenofovir disoproxil - tablet - 245mg

New Zealand - English - Medsafe (Medicines Safety Authority)

gilead sciences (nz) - efavirenz 600mg;  ;  ;  ; emtricitabine 200mg;  ;  ;  ; tenofovir disoproxil fumarate 300mg;  ;  ;   - film coated tablet - active: efavirenz 600mg       emtricitabine 200mg       tenofovir disoproxil fumarate 300mg       excipient: croscarmellose sodium hyprolose magnesium stearate microcrystalline cellulose opadry pink 85f94172 purified water sodium laurilsulfate - atripla is indicated for the treatment of hiv infected adults over the age of 18 years, alone or in combination with other antiretroviral agents.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

gilead sciences international ltd - tenofovir disoproxil - tablet - 245mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

gilead sciences international ltd - tenofovir disoproxil fumarate - granules - 33mg/1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

gilead sciences international ltd - tenofovir disoproxil fumarate - tablet - 123mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

gilead sciences international ltd - tenofovir disoproxil fumarate - tablet - 163mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

gilead sciences international ltd - tenofovir disoproxil fumarate - tablet - 204mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

gilead sciences international ltd - tenofovir disoproxil fumarate; emtricitabine; cobicistat; elvitegravir - tablet - 245mg ; 200mg ; 150mg ; 150mg

United States - English - NLM (National Library of Medicine)

gilead sciences, inc - ledipasvir (unii: 013te6e4wv) (ledipasvir - unii:013te6e4wv), sofosbuvir (unii: wj6ca3zu8b) (sofosbuvir - unii:wj6ca3zu8b) - ledipasvir 90 mg - harvoni is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis c virus (hcv) [see dosage and administration (2.2 and 2.3) and clinical studies (14)] : - genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis - genotype 1 infection with decompensated cirrhosis, for use in combination with ribavirin - genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, for use in combination with ribavirin if harvoni is administered with ribavirin, the contraindications to ribavirin also apply to this combination regimen. refer to the ribavirin prescribing information for a list of contraindications for ribavirin [see dosage and administration (2.2)] . risk summary if harvoni is administered with ribavirin, the combination regimen is contraindicated in pregnant women and in men whose female partners are pregnant. refer to the ribavirin prescribing information for more information on ribav

United States - English - NLM (National Library of Medicine)

gilead sciences, inc. - velpatasvir (unii: kcu0c7rs7z) (velpatasvir - unii:kcu0c7rs7z), sofosbuvir (unii: wj6ca3zu8b) (sofosbuvir - unii:wj6ca3zu8b) - velpatasvir 100 mg - epclusa is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 infection [see dosage and administration (2.2, 2.3, 2.4) and clinical studies (14)] : - without cirrhosis or with compensated cirrhosis - with decompensated cirrhosis for use in combination with ribavirin. epclusa and ribavirin combination regimen is contraindicated in patients for whom ribavirin is contraindicated. refer to the ribavirin prescribing information for a list of contraindications for ribavirin [see dosage and administration (2.2, 2.3, 2.4)]. risk summary if epclusa is administered with ribavirin, the combination regimen is contraindicated in pregnant women and in men whose female partners are pregnant. refer to the ribavirin prescribing information for more information on ribavirin-associated risks of use during pregnancy. no adequate human data are available to establish whether or not epclusa poses a risk to pregnancy outcomes. in